Aktiesnakken — Maj 2011
-
fokus på år ikke kvartaler
-
på daratumumab.
-
det går godt. og eskalerer dosis
-
responserate bliver endpoint
-
cost er ikke significant
-
rough guide
-
200 mill på cd20
-
80 på zalu
-
30 på dara
-
Fedt med svar!
-
Så er det Jeffries
-
Financials og expenses guidance
-
hvad sker der for jeres lave udgifter
-
og hvad med warrants udgifter
-
og så lidt ledelse
-
expenses will increase over året
-
145x 4 = 100 under expenses
-
men ca. 170 going forward
-
bottom end of the range
-
warrants er the run way
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind